Pacer Advisors’s Kalaris Therapeutics KLRS Stock Holding History

Pacer Advisors’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-76	Closed	-$41K	–	1571
2021 Q1	$41K	Buy	76 +35	+85%	+$29.4K	﹤0.01%	1463
2020 Q4	$37K	Buy	+41	New	+$31.5K	﹤0.01%	1442

Other funds holding KLRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Pacer Advisors's KLRS Position: Q2 2021 in Review

Pacer Advisors sold out of Kalaris Therapeutics (KLRS) in Q2 2021, closing a stake of 76 shares — an estimated $41K sold.

Pacer Advisors first reported a position in KLRS in Q4 2020 and held it in 2 quarters. The position peaked at $41K in Q1 2021. 84 funds tracked by Wall St. Rank hold KLRS as of Q2 2021.

Pacer Advisors reported no remaining Kalaris Therapeutics position as of Q2 2021 after selling out during the quarter.
Pacer Advisors sold 76 Kalaris Therapeutics shares in Q2 2021, an estimated $41K.
Pacer Advisors first reported a position in Kalaris Therapeutics in Q4 2020 and held it in 2 quarters.
Pacer Advisors's Kalaris Therapeutics position peaked at $41K in Q1 2021.
84 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.